Nasdaq
$88.42▲ 0.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $22.36BShares out 2.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 3d agoPre-market26.10.22 20:496-KKey event#●●●#●●●#●●●
BioNTech SEBullish
BioNTech has entered into a clinical trial collaboration and supply agreement with Gilead Sciences to evaluate the combination of its investigational bispecific immunomodulator, pumitamig, with Gilead’s TROP2-directed ADC, Trodelvy (sacituzumab govitecan). The global Phase 3 ROSETTA Breast-01 trial will be adapted to replace chemotherapy with Trodelvy as a first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer.…more
$88.42+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 6d agoPre-market26.10.19 20:266-KKey event
BioNTech SE
BioNTech will present 16 abstracts from its late-stage oncology pipeline at the ESMO 2026 Congress, held from October 23 to 27, 2026. Key highlights include initial Phase 2 clinical data for the PD-L1xVEGF-A bispecific immunomodulator pumitamig and results from its novel combination therapies with antibody-drug conjugates (ADCs).…more
$88.42+0.31%vs prev closeView filingShare - 10.13After-hours26.10.14 05:086-KKey event
BioNTech SE
BioNTech announced that its Phase 2/3 AHEAD-MERIT clinical trial for the mRNA cancer immunotherapy candidate BNT113 failed to meet the dual primary endpoint of progression-free survival (PFS). The trial will continue as planned to evaluate the second dual primary endpoint of overall survival (OS).…more
$88.42+0.31%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6h agoClosed26.10.25 16:30#●●●#●●●#●●●
BioNTech and BMS Report Positive Phase 2 Data for Lung Cancer Drug Pumitamig…more
BioNTech and Bristol Myers Squibb announced encouraging Phase 2 clinical trial results for their lung cancer candidate, pumitamig, showing improved antitumor activity. As these are early-stage findings, further clinical validation and regulatory approval processes remain necessary.…more
$88.42+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 3d agoPre-market26.10.22 19:48
●●●●●●●● ●●●●● ●●●●●●
BioNTech and Gilead Sciences have entered a collaboration to evaluate a combination of pumitamig and sacituzumab govitecan in a Phase 3 trial for triple-negative breast cancer. The partnership aims to adapt the trial to current standards of care to potentially improve patient outcomes.…more
$88.42+0.31%vs prev closeShareBenzinga - 3d agoPre-market26.10.22 19:45
●●●●●●●● ●●●●● ●●●●●●
BioNTech is collaborating with Gilead Sciences to evaluate its investigational drug 'pumitamig' in combination with sacituzumab govitecan for triple-negative breast cancer. While the trial aims to improve treatment standards, the project remains in the clinical development stage without immediate financial impact.…more
$88.42+0.31%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report